IPO最新受理2家，都来自浙江

Group 1: Ningbo Jianxin Superconducting Technology Co., Ltd. IPO - The company is primarily engaged in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with a mission to make MRI accessible for everyday diagnosis [5][6] - The company reported a revenue of 425.50 million yuan in 2024, a decrease from 450.64 million yuan in 2023, while the net profit attributable to the parent company increased to 50.27 million yuan [8][9] - The company has a strong customer base, with the top five clients contributing over 73% of total revenue, including major players like Fujifilm and GE Healthcare [5][6][8] - The company plans to raise 865 million yuan through its IPO, with funds allocated for projects including the production of superconducting magnets and technological upgrades [12] Group 2: Hangzhou Lianchuan Biotechnology Co., Ltd. IPO - The company focuses on gene technology, providing various gene testing services primarily to universities and research institutions [15][16] - The company achieved a revenue of 366.76 million yuan in 2024, up from 286.59 million yuan in 2023, with a net profit of 56.66 million yuan [18][19] - The company plans to raise 300 million yuan through its IPO, with funds directed towards expanding its gene technology service platform and developing molecular diagnostic reagents [21][22] - The company faces risks due to its reliance on Illumina, a major supplier that has been placed on an unreliable entity list, which could impact its operations if supply issues arise [23][25]